

Johanneke E A Portielje

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4870581/publications.pdf>

Version: 2024-02-01

50
papers

1,669
citations

331670

21
h-index

302126

39
g-index

50
all docs

50
docs citations

50
times ranked

2733
citing authors

#	ARTICLE	IF	CITATIONS
1	DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. <i>Lancet Oncology, The</i> , 2018, 19, 1459-1467.	10.7	238
2	Frailty and malnutrition predictive of mortality risk in older patients with advanced colorectal cancer receiving chemotherapy. <i>Journal of Geriatric Oncology</i> , 2013, 4, 218-226.	1.0	175
3	IL-12: a promising adjuvant for cancer vaccination. <i>Cancer Immunology, Immunotherapy</i> , 2003, 52, 133-144.	4.2	107
4	Validity of Adjuvant! Online program in older patients with breast cancer: a population-based study. <i>Lancet Oncology, The</i> , 2014, 15, 722-729.	10.7	81
5	Performing Survival Analyses in the Presence of Competing Risks: A Clinical Example in Older Breast Cancer Patients. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv366.	6.3	79
6	Deciding about (neo-)adjuvant rectal and breast cancer treatment: Missed opportunities for shared decision making. <i>Acta OncolÃ³gica</i> , 2016, 55, 134-139.	1.8	68
7	Repeated administrations of interleukin (IL)-12 are associated with persistently elevated plasma levels of IL-10 and declining IFN-gamma, tumor necrosis factor-alpha, IL-6, and IL-8 responses. <i>Clinical Cancer Research</i> , 2003, 9, 76-83.	7.0	68
8	A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy. <i>European Journal of Cancer</i> , 2019, 107, 60-67.	2.8	65
9	Variation in treatment and survival of older patients with non-metastatic breast cancer in five European countries: a population-based cohort study from the EURECCA Breast Cancer Group. <i>British Journal of Cancer</i> , 2018, 119, 121-129.	6.4	62
10	Randomized Phase II Study Comparing Efficacy and Safety of Combination-Therapy Trastuzumab and Docetaxel vs. Sequential Therapy of Trastuzumab Followed by Docetaxel Alone at Progression As First-Line Chemotherapy in Patients with HER2+ Metastatic Breast Cancer: HERTAX Trial. <i>Clinical Breast Cancer</i> , 2011, 11, 103-113.	2.4	61
11	Use of implicit persuasion in decision making about adjuvant cancer treatment: A potential barrier to shared decision making. <i>European Journal of Cancer</i> , 2016, 66, 55-66.	2.8	53
12	Nationwide trends in chemotherapy use and survival of elderly patients with metastatic pancreatic cancer. <i>Cancer Medicine</i> , 2017, 6, 2840-2849.	2.8	41
13	Risk stratification for surgical outcomes in older colorectal cancer patients using ISAR-HP and G8 screening tools. <i>Journal of Geriatric Oncology</i> , 2018, 9, 110-114.	1.0	40
14	Physical Functioning in Older Patients With Breast Cancer: A Prospective Cohort Study in the TEAM Trial. <i>Oncologist</i> , 2016, 21, 946-953.	3.7	35
15	The Effect of A Geriatric Assessment on Treatment Decisions for Patients with Lung Cancer. <i>Lung</i> , 2017, 195, 225-231.	3.3	35
16	Prognostic Value of Geriatric 8 and Identification of Seniors at Risk for Hospitalized Patients Screening Tools for Patients With Lung Cancer. <i>Clinical Lung Cancer</i> , 2017, 18, 660-666.e1.	2.6	34
17	A Prospective Comparison of Younger and Older Patients' Preferences for Adjuvant Chemotherapy and Hormonal Therapy in Early Breast Cancer. <i>Clinical Breast Cancer</i> , 2016, 16, 379-388.	2.4	33
18	Bevacizumab combined with docetaxel, oxaliplatin, and capecitabine, followed by maintenance with capecitabine and bevacizumab, as first-line treatment of patients with advanced HER2-negative gastric cancer: A multicenter phase 2 study. <i>Cancer</i> , 2016, 122, 1434-1443.	4.1	31

#	ARTICLE	IF	CITATIONS
19	Trastuzumab and bevacizumab combined with docetaxel, oxaliplatin and capecitabine as first-line treatment of advanced HER2-positive gastric cancer: a multicenter phase II study. <i>Investigational New Drugs</i> , 2016, 34, 119-128.	2.6	30
20	Subcutaneous injection of interleukin 12 induces systemic inflammatory responses in humans: implications for the use of IL-12 as vaccine adjuvant. <i>Cancer Immunology, Immunotherapy</i> , 2005, 54, 37-43.	4.2	27
21	Impact of Comorbidities and Age on Cause-Specific Mortality in Postmenopausal Patients with Breast Cancer. <i>Oncologist</i> , 2019, 24, e467-e474.	3.7	26
22	Treatment and survival of rectal cancer patients over the age of 80 years: a EURECCA international comparison. <i>British Journal of Cancer</i> , 2018, 119, 517-522.	6.4	24
23	Interleukin 12 induces activation of fibrinolysis and coagulation in humans. <i>British Journal of Haematology</i> , 2001, 112, 499-505.	2.5	19
24	Can physical prehabilitation prevent complications after colorectal cancer surgery in frail older patients?. <i>European Journal of Surgical Oncology</i> , 2021, 47, 2830-2840.	1.0	19
25	Treatment and Survival of Patients with Colon Cancer Aged 80 Years and Older: A EURECCA International Comparison. <i>Oncologist</i> , 2018, 23, 982-990.	3.7	17
26	Impact of Older Age and Comorbidity on Locoregional and Distant Breast Cancer Recurrence: A Large Population-Based Study. <i>Oncologist</i> , 2020, 25, e24-e30.	3.7	15
27	Development and validation of the PORTRET tool to predict recurrence, overall survival, and other-cause mortality in older patients with breast cancer in the Netherlands: a population-based study. <i>The Lancet Healthy Longevity</i> , 2021, 2, e704-e711.	4.6	14
28	Methionine-Enkephalin in Migraine and Tension Headache. Differences Between Classic Migraine, Common Migraine and Tension Headache, and Changes During Attacks.. <i>Headache</i> , 1990, 30, 160-164.	3.9	13
29	Risk prediction models for postoperative outcomes of colorectal cancer surgery in the older population - a systematic review. <i>Journal of Geriatric Oncology</i> , 2020, 11, 1217-1228.	1.0	13
30	Metastatic breast cancer in older patients: A longitudinal assessment of geriatric outcomes. <i>Journal of Geriatric Oncology</i> , 2020, 11, 969-975.	1.0	11
31	Toxicity, Response and Survival in Older Patients with Metastatic Melanoma Treated with Checkpoint Inhibitors. <i>Cancers</i> , 2021, 13, 2826.	3.7	11
32	Evaluation and Implementation of ListeningTime: A Web-Based Preparatory Communication Tool for Elderly Patients With Cancer and Their Health Care Providers. <i>JMIR Cancer</i> , 2019, 5, e11556.	2.4	11
33	Effectiveness of radiotherapy after breast-conserving surgery in older patients with T1-2N0 breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 178, 637-645.	2.5	10
34	The impact of colorectal surgery on health-related quality of life in older functionally dependent patients with cancer – A longitudinal follow-up study. <i>Journal of Geriatric Oncology</i> , 2019, 10, 724-732.	1.0	10
35	Discontinuation of adjuvant endocrine therapy and impact on quality of life and functional status in older patients with breast cancer. <i>Breast Cancer Research and Treatment</i> , 2022, 193, 567-577.	2.5	10
36	Validation of the ACS NSQIP surgical risk calculator in older patients with colorectal cancer undergoing elective surgery. <i>Journal of Geriatric Oncology</i> , 2022, 13, 788-795.	1.0	10

#	ARTICLE	IF	CITATIONS
37	Treatment and Survival of Elderly Patients with Stage II Pancreatic Cancer: A Report of the EURECCA Pancreas Consortium. <i>Annals of Surgical Oncology</i> , 2020, 27, 5337-5346.	1.5	9
38	Predicting disease-related and patient-reported outcomes in older patients with breast cancer - a systematic review. <i>Journal of Geriatric Oncology</i> , 2021, 12, 696-704.	1.0	9
39	A Prediction Model for Severe Complications after Elective Colorectal Cancer Surgery in Patients of 70 Years and Older. <i>Cancers</i> , 2021, 13, 3110.	3.7	8
40	Independent replication of polymorphisms predicting toxicity in breast cancer patients randomized between dose-dense and docetaxel-containing adjuvant chemotherapy. <i>Oncotarget</i> , 2017, 8, 113531-113542.	1.8	8
41	A randomized phase 2 study exploring the role of bevacizumab and a chemotherapy-free approach in HER2-positive metastatic breast cancer: The HAT study (BOOG 2008-2003), a Dutch Breast Cancer Research Group trial. <i>Cancer</i> , 2016, 122, 2961-2970.	4.1	7
42	Prediction of Other-Cause Mortality in Older Patients with Breast Cancer Using Comorbidity. <i>Cancers</i> , 2021, 13, 1627.	3.7	7
43	Daily Oral Ibandronate With Adjuvant Endocrine Therapy in Postmenopausal Women With Estrogen Receptor-Positive Breast Cancer (BOOG 2006-04): Randomized Phase III TEAM-IIB Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 2934-2945.	1.6	6
44	Differences in treatment and survival of older patients with operable breast cancer between the United Kingdom and the Netherlands – A comparison of two national prospective longitudinal multi-centre cohort studies. <i>European Journal of Cancer</i> , 2022, 163, 189-199.	2.8	5
45	Survival of surgical and non-surgical older patients with non-metastatic colorectal cancer: A population-based study in the Netherlands. <i>European Journal of Surgical Oncology</i> , 2021, 47, 3144-3150.	1.0	4
46	Differential Survival and Therapy Benefit of Patients with Breast Cancer Are Characterized by Distinct Epithelial and Immune Cell Microenvironments. <i>Clinical Cancer Research</i> , 2022, 28, 960-971.	7.0	4
47	Effects of controlled ovarian stimulation on toxicity of TAC chemotherapy in early breast cancer patients. <i>Cancer Management and Research</i> , 2018, Volume 10, 3931-3935.	1.9	2
48	Early stage breast cancer treatment and outcome of older patients treated in an oncogeriatric care and a standard care setting: an international comparison. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 519-526.	2.5	2
49	Fostering Patient Choice Awareness and Presenting Treatment Options Neutrally: A Randomized Trial to Assess the Effect on Perceived Room for Involvement in Decision Making. <i>Medical Decision Making</i> , 2022, 42, 375-386.	2.4	2
50	Abstract PS6-08: The PORTRET-tool: A prediction tool for older patients with breast cancer that predicts recurrence, survival and other-cause mortality. , 2021, , .		0